1.
Tumori
; 98(5): 139e-142e, 2012.
Artículo
en Inglés
| MEDLINE
| ID: mdl-23235770
RESUMEN
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.